Inhibrx Biosciences Inc.(INBX)

Biotechnology · La Jolla, CA

$94.70+0.14 (+0.15%)

Delayed quote: Oct 6, 2026, 10:25 AM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T14:26:51.812Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:26:51.812Z.

Quote observation: 2026-10-06T14:25:06.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,389,361,314
Total debt · period ending 2026-06-30: 5,341,000
Cash · period ending 2026-06-30: 133,344,000
TTM free cash flow · period ending 2026-06-30: -131,926,000

FMP input reference: 771dc6670e9772695969b0bf6104b917a4d7f40f340cdb77ec2424dd20cacd43

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

INBX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

INBX Competitors' EV/FCF Ratio

INBX

Inhibrx Biosciences Inc.

Current

Market Cap

$1.39B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANAB

AnaptysBio, Inc.

vs INBX

Market Cap

$1.41B

EV/FCF Ratio

85.92x

TTM Avg

263.63x

3Y Avg

263.63x

5Y Avg

163.80x

KLRA

Kailera Therapeutics, Inc.

vs INBX

Market Cap

$1.34B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MAZE

Maze Therapeutics, Inc.

vs INBX

Market Cap

$1.44B

EV/FCF Ratio

N/A

TTM Avg

4.64x

3Y Avg

4.64x

5Y Avg

4.64x

AVBP

ArriVent BioPharma, Inc.

vs INBX

Market Cap

$557.04M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs INBX

Market Cap

$1.32B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BRVE

Braveheart Bio, Inc.

vs INBX

Market Cap

$1.43B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HCSG

Healthcare Services Group, Inc.

vs INBX

Market Cap

$1.46B

EV/FCF Ratio

8.69x

TTM Avg

9.15x

3Y Avg

21.82x

5Y Avg

100.71x

DRTS

Alpha Tau Medical Ltd

vs INBX

Market Cap

$1.31B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GHRS

GH Research PLC

vs INBX

Market Cap

$1.48B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Inhibrx Biosciences Inc. (INBX)	$1.39B	N/A	N/A	N/A	N/A
AnaptysBio, Inc. (ANAB)vs ›	$1.41B	85.92x	263.63x	263.63x	163.80x
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.34B	N/A	N/A	N/A	N/A
Maze Therapeutics, Inc. (MAZE)vs ›	$1.44B	N/A	4.64x	4.64x	4.64x
ArriVent BioPharma, Inc. (AVBP)vs ›	$557.04M	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.32B	N/A	N/A	N/A	N/A
Braveheart Bio, Inc. (BRVE)vs ›	$1.43B	N/A	N/A	N/A	N/A
Healthcare Services Group, Inc. (HCSG)vs ›	$1.46B	8.69x	9.15x	21.82x	100.71x
Alpha Tau Medical Ltd (DRTS)vs ›	$1.31B	N/A	N/A	N/A	N/A
GH Research PLC (GHRS)vs ›	$1.48B	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

INBX EV/FCF Ratio Metrics

INBX Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics